Fundamentals for IDEXX Laboratories, Inc.
Analysts have maintained a buy bias for IDXX, which could prompt investors to consider the stock as a viable investment. With this positive outlook, IDXX is positioned as a...
Business Operations:
Sector: HealthcareIndustry: Diagnostics & Research
IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. It operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. The company offers point-of-care diagnostic solutions, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology/morphology, and coagulation analyzers; and SNAP rapid assays test kits. It also provides commercial reference laboratory diagnostic and consulting services to veterinarians; veterinary consultation, telemedicine, and advisory services, including radiology, dental radiography, cardiology, internal medicine, and ultrasound consulting; Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, Quanti-Tray products, and Tecta system instruments; UV Viewer Plus, a UV light cabinet which aids in the visual interpretation of fluorescent-based water tests; and veterinary software and services for independent veterinary clinics and corporate groups. In addition, the company offers diagnostic tests, services, and related instrumentation to manage the health status of livestock and poultry; human medical diagnostic products and services; and VetConnect PLUS, a cloud-based technology that enables veterinarians to access and analyze patients, as well as operates VetLab Station. It markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
Revenue projections:
Financial Ratios:
| currentRatio | 1.172000 |
|---|---|
| forwardPE | 30.972288 |
| debtToEquity | 67.971000 |
| earningsGrowth | 0.176000 |
| revenueGrowth | 0.097000 |
| grossMargins | 0.624460 |
| operatingMargins | 0.349800 |
| trailingEps | 14.240000 |
| forwardEps | 16.737220 |
A current ratio of 1.172 for IDEXX Laboratories, Inc. implies that the company has ample liquidity to meet its short-term debts. IDEXX Laboratories, Inc.'s cash reserves and current assets should easily cover these obligations, highlighting its financial stability and ability to manage short-term liabilities.
IDXX's positive gross and operating margins highlight its strong profitability. The company's ability to control costs while generating revenue indicates efficient operations and a healthy financial position.
IDEXX Laboratories, Inc.'s forward EPS exceeds its trailing EPS, indicating that the company is projected to be more profitable in the current financial year compared to the previous one. This suggests positive growth and improved earnings, signaling an optimistic outlook for IDEXX Laboratories, Inc.'s financial performance.
Price projections:
Insider Transactions:
11 sell transactions of IDXX were recorded, with market price hovering near 640.4509110884233.No sell transactions took place in the period under consideration.The trend of more buys than sells at IDXX's current price levels suggests a possible bullish sentiment. This could indicate that investors are expecting a favorable outlook for the stock, prompting more buying activity.
Recommendation changes over time:
Analysts have maintained a buy bias for IDXX, which could prompt investors to consider the stock as a viable investment. With this positive outlook, IDXX is positioned as an attractive option for those looking to park their money in a stable and potentially lucrative company.
